Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
Courrèges
J-P
JP
Vilsbøll
T
T
Zdravkovic
M
M
Le-Thi
T
T
Krarup
T
T
Schmitz
O
O
Verhoeven
R
R
Bugáñová
I
I
Madsbad
S
S
D015415:Biomarkers; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D004334:Drug Administration Schedule; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000069450:Liraglutide; D012307:Risk Factors
D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1